Bajaj Healthcare Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹166Cr
- +11.4% YoY
- +8.5% QoQ
- Net profit
- ₹14Cr
- +16.7% YoY
- Turned profitable QoQ
- Margin
- 17%
- +1 pp YoY
- +2 pp QoQ
Guidance rank: #83 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28. Revenue growth guidance for FY27 and FY28: 10% to 15% annually.
From Bajaj Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28.
- Peptide manufacturing plant (250 kg capacity) commissioning is targeted for Q4 FY27 with commercial revenue starting in 2028; expected peak revenue from this plant is INR 200-300 crores with EBITDA margins of 18%-20%.
- Oncology API facility is planned for commercialization by Q4 FY28.
- Expects near-term revenue from novel drugs such as Cenobamate (~INR 10-12 crores in FY27) and Suvorexant (commercialization by Q4 FY28).
- Longer-term top-line target is around INR 900-1000 crores within 2-3 years.
2 more points from Bajaj Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bajaj Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing and planned capital expenditure of INR 40-50 crores annually for the next few years.
- Commissioning of a dedicated peptide manufacturing facility (capacity ~250 kg per annum) targeted by Q4 FY27.
- Construction of a dedicated oncology API manufacturing facility planned for commissioning by Q4 FY28.
- Expansion of DSIR-approved R&D centre at Savli into a large 10,000 sq ft facility expected operational by August 2026.
- Acquisition of GenRx Pharmaceutical manufacturing facility in Nashik, under NCLT approval, to strengthen formulation and oncology business.
2 more points from Bajaj Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bajaj Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Bajaj Healthcare Ltd's call on order book
Create a free account to keep reading this call
Bajaj Healthcare Ltd — Quarterly revenue & net profit
Bajaj Healthcare Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 166 | 149 | +11.4% | 153 | +8.5% |
| Operating profit (EBITDA) | 29 | 25 | +16% | 23 | +26.1% |
| Operating margin | 17% | 16% | +1 pp | 15% | +2 pp |
| Profit before tax | 16 | 14 | +14.3% | -24 | — |
| Net profit (PAT) | 14 | 12 | +16.7% | -23 | — |
| EPS (₹) | 4.07 | 3.75 | +8.5% | -6.79 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹176 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bajaj Healthcare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bajaj Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bajaj Healthcare Ltd Q1 FY27 results?
Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28. Revenue growth guidance for FY27 and FY28: 10% to 15% annually.
What is Bajaj Healthcare Ltd share price analysis?
Bajaj Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 19.8 with a market cap of ₹1,113 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bajaj Healthcare Ltd planning capital expenditure?
Ongoing and planned capital expenditure of INR 40-50 crores annually for the next few years.
Keep Bajaj Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
